JP2017522871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522871A5 JP2017522871A5 JP2017501287A JP2017501287A JP2017522871A5 JP 2017522871 A5 JP2017522871 A5 JP 2017522871A5 JP 2017501287 A JP2017501287 A JP 2017501287A JP 2017501287 A JP2017501287 A JP 2017501287A JP 2017522871 A5 JP2017522871 A5 JP 2017522871A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- region
- cdr2
- cdr1
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 200
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 claims description 45
- 229940127121 immunoconjugate Drugs 0.000 claims description 38
- 229940127089 cytotoxic agent Drugs 0.000 claims description 31
- 239000002254 cytotoxic agent Substances 0.000 claims description 29
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 29
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 18
- 108010023337 axl receptor tyrosine kinase Proteins 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 101150022345 GAS6 gene Proteins 0.000 claims description 8
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 8
- 230000000981 bystander Effects 0.000 claims description 8
- 108010093470 monomethyl auristatin E Proteins 0.000 claims description 8
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 108010059074 monomethylauristatin F Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- MSNVESLISHTIRS-UHFFFAOYSA-N 9h-pyrrolo[2,1-c][1,4]benzodiazepine Chemical compound N1=C2C=CC=CC2=CN2CC=CC2=C1 MSNVESLISHTIRS-UHFFFAOYSA-N 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 241000282567 Macaca fascicularis Species 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 230000003302 anti-idiotype Effects 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical group C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 claims description 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 239000012624 DNA alkylating agent Substances 0.000 claims description 2
- 241000206602 Eukaryota Species 0.000 claims description 2
- 102100031487 Growth arrest-specific protein 6 Human genes 0.000 claims description 2
- 101000923005 Homo sapiens Growth arrest-specific protein 6 Proteins 0.000 claims description 2
- 229930126263 Maytansine Natural products 0.000 claims description 2
- 102000029749 Microtubule Human genes 0.000 claims description 2
- 108091022875 Microtubule Proteins 0.000 claims description 2
- 208000002231 Muscle Neoplasms Diseases 0.000 claims description 2
- 230000004988 N-glycosylation Effects 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 2
- 102000004243 Tubulin Human genes 0.000 claims description 2
- 108090000704 Tubulin Proteins 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 108010044540 auristatin Proteins 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims description 2
- 229930195731 calicheamicin Natural products 0.000 claims description 2
- 229960002173 citrulline Drugs 0.000 claims description 2
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 2
- 201000010918 connective tissue cancer Diseases 0.000 claims description 2
- 239000003431 cross linking reagent Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims description 2
- 229930188854 dolastatin Natural products 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims description 2
- 229960005501 duocarmycin Drugs 0.000 claims description 2
- 229930184221 duocarmycin Natural products 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 208000010749 gastric carcinoma Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 210000004688 microtubule Anatomy 0.000 claims description 2
- 201000002077 muscle cancer Diseases 0.000 claims description 2
- 210000000653 nervous system Anatomy 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000000498 stomach carcinoma Diseases 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 208000003200 Adenoma Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 238000012575 bio-layer interferometry Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201400380 | 2014-07-11 | ||
| DKPA201400380 | 2014-07-11 | ||
| DKPA201400489 | 2014-09-01 | ||
| DKPA201400489 | 2014-09-01 | ||
| DKPA201400746 | 2014-12-22 | ||
| DKPA201400746 | 2014-12-22 | ||
| DKPA201500283 | 2015-05-12 | ||
| DKPA201500283 | 2015-05-12 | ||
| PCT/EP2015/065900 WO2016005593A1 (en) | 2014-07-11 | 2015-07-10 | Antibodies binding axl |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020080943A Division JP2020141682A (ja) | 2014-07-11 | 2020-05-01 | Ａｘｌに結合する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522871A JP2017522871A (ja) | 2017-08-17 |
| JP2017522871A5 true JP2017522871A5 (enExample) | 2018-08-16 |
| JP6701162B2 JP6701162B2 (ja) | 2020-05-27 |
Family
ID=53673928
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017501287A Active JP6701162B2 (ja) | 2014-07-11 | 2015-07-10 | Ａｘｌに結合する抗体 |
| JP2020080943A Pending JP2020141682A (ja) | 2014-07-11 | 2020-05-01 | Ａｘｌに結合する抗体 |
| JP2023198745A Pending JP2024026158A (ja) | 2014-07-11 | 2023-11-24 | Ａｘｌに結合する抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020080943A Pending JP2020141682A (ja) | 2014-07-11 | 2020-05-01 | Ａｘｌに結合する抗体 |
| JP2023198745A Pending JP2024026158A (ja) | 2014-07-11 | 2023-11-24 | Ａｘｌに結合する抗体 |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US10512688B2 (enExample) |
| EP (2) | EP3169706B1 (enExample) |
| JP (3) | JP6701162B2 (enExample) |
| KR (2) | KR20230146665A (enExample) |
| CN (2) | CN114621347A (enExample) |
| AU (3) | AU2015286569B2 (enExample) |
| CA (1) | CA2952758A1 (enExample) |
| CY (1) | CY1122721T1 (enExample) |
| DK (1) | DK3169706T3 (enExample) |
| EA (1) | EA201790173A1 (enExample) |
| ES (1) | ES2774428T3 (enExample) |
| HR (1) | HRP20200283T1 (enExample) |
| HU (1) | HUE048667T2 (enExample) |
| IL (2) | IL296633A (enExample) |
| LT (1) | LT3169706T (enExample) |
| ME (1) | ME03665B (enExample) |
| MX (1) | MX370807B (enExample) |
| NZ (1) | NZ728019A (enExample) |
| PL (1) | PL3169706T3 (enExample) |
| PT (1) | PT3169706T (enExample) |
| RS (1) | RS60012B1 (enExample) |
| SG (2) | SG10202006715SA (enExample) |
| SI (1) | SI3169706T1 (enExample) |
| SM (1) | SMT202000265T1 (enExample) |
| UA (1) | UA127198C2 (enExample) |
| WO (1) | WO2016005593A1 (enExample) |
| ZA (1) | ZA201608609B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2952758A1 (en) | 2014-07-11 | 2016-01-14 | Genmab A/S | Antibodies binding axl |
| SMT202000359T1 (it) * | 2015-07-10 | 2020-09-10 | Genmab As | Coniugati anticorpo-farmaco specifici per axl per il trattamento del cancro |
| KR20180101479A (ko) | 2016-01-13 | 2018-09-12 | 젠맵 에이/에스 | 항체 및 그의 약물 접합체를 위한 제제 |
| CN109563164A (zh) | 2016-04-15 | 2019-04-02 | 生物蛋白有限公司 | 抗axl抗体、抗体片段和它们的免疫缀合物以及其用途 |
| EP3458482A4 (en) | 2016-05-20 | 2020-01-15 | Agency for Science, Technology and Research | ANTI-AXL TYROSINE KINASEPEPTOR ANTIBODIES AND USES THEREOF |
| SG11201809751XA (en) | 2016-05-26 | 2018-12-28 | Zeno Royalties & Milestones Llc | Egfr inhibitor compounds |
| EP3481868A1 (en) * | 2016-07-08 | 2019-05-15 | Genmab A/S | New dosage regimens for antibody drug conjugates based on anti-axl antibodies |
| SG10202101958YA (en) * | 2016-08-31 | 2021-03-30 | Agency Science Tech & Res | Methods for the identification, targeting and isolation of human dendritic cell (dc) precursors "pre-dc" and their uses thereof |
| CN108285487B (zh) * | 2017-01-08 | 2021-02-19 | 浙江昭华生物医药有限公司 | 抗5t4抗体-药物偶联物及其应用 |
| JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| SG11202002331QA (en) | 2017-09-13 | 2020-04-29 | Nat Res Council Canada | Axl-specific antibodies and uses thereof |
| CN107987163B (zh) * | 2017-12-04 | 2018-11-20 | 杭州尚健生物技术有限公司 | 单克隆抗体9a及其应用 |
| CA3095986A1 (en) * | 2018-04-10 | 2019-10-17 | Genmab A/S | Axl-specific antibodies for cancer treatment |
| CN110483639A (zh) | 2018-05-15 | 2019-11-22 | 复旦大学 | 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途 |
| CA3104390A1 (en) | 2018-06-22 | 2019-12-26 | Genmab A/S | Method for producing a controlled mixture of two or more different antibodies |
| JP2022502411A (ja) * | 2018-09-26 | 2022-01-11 | ゲンマブ エー／エス | 非小細胞肺がんの処置のためのａｘｌ特異的抗体 |
| AU2019372436A1 (en) * | 2018-11-01 | 2021-05-20 | Merck Patent Gmbh | Methods of administering anti-TIM-3 antibodies |
| US20220308062A1 (en) * | 2019-05-07 | 2022-09-29 | Board Of Regents, The University Of Texas System | Methods for predicting drug responsiveness in samples from cancer subjects |
| US20220273809A1 (en) * | 2019-07-19 | 2022-09-01 | Genmab A/S | Axl antibody-drug conjugates for use in treating cancer |
| CN118465272B (zh) * | 2019-12-04 | 2025-08-19 | 珠海泰诺麦博制药股份有限公司 | 抗人巨细胞病毒抗体及其用途 |
| AU2021205893A1 (en) | 2020-01-08 | 2022-06-23 | Synthis Therapeutics, Inc. | ALK5 inhibitor conjugates and uses thereof |
| CA3192239A1 (en) * | 2020-08-19 | 2022-02-24 | Pharmabcine Inc. | Modified antibody and method for manufacturing same |
| WO2022164288A1 (ko) | 2021-01-29 | 2022-08-04 | 한국과학기술원 | 비염증성 식세포작용 유도 활성을 갖는 융합분자 |
| AU2021451307A1 (en) * | 2021-06-16 | 2024-02-01 | Shanghai Sinobay Biotechnology Co., Ltd. | Antibody targeting axl protein and antigen binding fragment thereof, preparation method therefor and use thereof |
| WO2022269605A1 (en) | 2021-06-24 | 2022-12-29 | Yeda Research And Development Co. Ltd. | Combination therapy for the treatment of cancer comprising an anti-egfr antibody and an axl-inhibitor |
| CN119968395A (zh) * | 2022-08-18 | 2025-05-09 | 百进生物科技公司 | 抗axl抗体、其抗原结合片段及其制备和使用方法 |
| PL446349A1 (pl) * | 2023-10-11 | 2025-04-14 | Celon Pharma Spółka Akcyjna | Przeciwciała bispecyficzne anty-AXL i anty-PD-L1 oraz ich zastosowanie w terapii, zwłaszcza w leczeniu nowotworu |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP0486622B1 (en) | 1989-08-09 | 1998-11-04 | Rhomed, Incorporated | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| CA2113113A1 (en) | 1991-07-08 | 1993-01-21 | Simon W. Kantor | Thermotropic liquid crystal segmented block copolymer |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| DK1150918T3 (da) | 1999-02-03 | 2004-12-20 | Biosante Pharmaceuticals Inc | Fremgangsmåde til fremstilling af terapeutiske calciumphosphatpartikler |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| MXPA02000962A (es) | 1999-07-29 | 2002-07-02 | Medarex Inc | Anticuerpos monoclonales humanos para her2/neu. |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| NZ529788A (en) | 2001-05-31 | 2003-12-19 | Medarex Inc | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
| JP4836451B2 (ja) | 2002-07-18 | 2011-12-14 | メルス ベー ヴェー | 抗体混合物の組換え生産 |
| CA2802205C (en) | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| EP1560599A1 (en) | 2002-11-14 | 2005-08-10 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| CN103394083B (zh) | 2003-11-06 | 2017-07-18 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| US8158590B2 (en) | 2005-08-05 | 2012-04-17 | Syntarga B.V. | Triazole-containing releasable linkers, conjugates thereof, and methods of preparation |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2007059782A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| US8940784B2 (en) | 2006-02-02 | 2015-01-27 | Syntarga B.V. | Water-soluble CC-1065 analogs and their conjugates |
| US7951918B2 (en) | 2006-03-17 | 2011-05-31 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| AR060070A1 (es) | 2006-03-24 | 2008-05-21 | Merck Patent Gmbh | Dominios proteicos heterodimericos obtenidos por ingenieria |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| EP2070956A1 (en) | 2007-12-14 | 2009-06-17 | Total Petrochemicals Research Feluy | Process for the production of a bimodal polypropylene having low ash content |
| ES2702087T3 (es) | 2007-06-21 | 2019-02-27 | Macrogenics Inc | Diacuerpos covalentes y sus usos |
| US8680293B2 (en) | 2007-08-01 | 2014-03-25 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| RU2559530C2 (ru) | 2007-11-15 | 2015-08-10 | Чугаи Сейяку Кабусики Кайся | Моноклональные антитела, способные связываться с белком axl, и их применение |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| PL2235064T3 (pl) | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| JP5397668B2 (ja) | 2008-09-02 | 2014-01-22 | ソニー株式会社 | 記憶素子および記憶装置 |
| RU2562232C2 (ru) | 2008-11-03 | 2015-09-10 | Синтарга Б.В. | Новые аналоги сс-1065 и их конъюгаты |
| ES2986435T3 (es) | 2008-12-19 | 2024-11-11 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| RU2011151069A (ru) * | 2009-05-15 | 2013-06-20 | Чугаи Сейяку Кабусики Кайся | Анти-axl антитело |
| AR077595A1 (es) * | 2009-07-27 | 2011-09-07 | Genentech Inc | Tratamientos de combinacion |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| US9074192B2 (en) | 2010-01-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| EP4477668A3 (en) | 2010-04-20 | 2025-03-19 | Genmab A/S | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| EP2582729A4 (en) * | 2010-06-18 | 2014-05-28 | Hoffmann La Roche | ANTI-AXL ANTIBODIES AND METHOD FOR THEIR USE |
| CA2807269A1 (en) | 2010-08-24 | 2012-03-01 | Roche Glycart Ag | Activatable bispecific antibodies |
| WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
| US9562109B2 (en) | 2010-11-05 | 2017-02-07 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| BR112013032899A2 (pt) * | 2011-06-22 | 2017-01-24 | Inserm Inst Nat De La Santé Et De La Rech Médicale | anticorpos anti-axl e utilizações dos mesmos |
| US9249228B2 (en) | 2011-06-22 | 2016-02-02 | Oribase Pharma | Anti-Axl antibodies and uses thereof |
| EP2589609A1 (en) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| US9879061B2 (en) | 2011-12-15 | 2018-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis |
| EP2850059A4 (en) | 2012-05-15 | 2016-06-29 | Concortis Biosystems Corp | CONJUGATES OF MEDICATION, METHODS OF CONJUGATION AND USE THEREOF |
| US9624308B2 (en) | 2012-11-05 | 2017-04-18 | Pierre Fabre Medicament | Antigen binding proteins |
| WO2014174111A1 (en) | 2013-04-26 | 2014-10-30 | Pierre Fabre Medicament | Axl antibody-drug conjugate and its use for the treatment of cancer |
| GB201410825D0 (en) | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| CA2952758A1 (en) | 2014-07-11 | 2016-01-14 | Genmab A/S | Antibodies binding axl |
| EP3229836B1 (en) | 2014-12-09 | 2019-11-13 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Human monoclonal antibodies against axl |
| SMT202000359T1 (it) | 2015-07-10 | 2020-09-10 | Genmab As | Coniugati anticorpo-farmaco specifici per axl per il trattamento del cancro |
-
2015
- 2015-07-10 CA CA2952758A patent/CA2952758A1/en active Pending
- 2015-07-10 CN CN202210136603.9A patent/CN114621347A/zh active Pending
- 2015-07-10 RS RS20200253A patent/RS60012B1/sr unknown
- 2015-07-10 ME MEP-2020-42A patent/ME03665B/me unknown
- 2015-07-10 HU HUE15738884A patent/HUE048667T2/hu unknown
- 2015-07-10 EP EP15738884.4A patent/EP3169706B1/en active Active
- 2015-07-10 SM SM20200265T patent/SMT202000265T1/it unknown
- 2015-07-10 US US15/325,364 patent/US10512688B2/en active Active
- 2015-07-10 DK DK15738884.4T patent/DK3169706T3/da active
- 2015-07-10 SG SG10202006715SA patent/SG10202006715SA/en unknown
- 2015-07-10 MX MX2016016881A patent/MX370807B/es active IP Right Grant
- 2015-07-10 UA UAA201701193A patent/UA127198C2/uk unknown
- 2015-07-10 CN CN201580045131.4A patent/CN107074948B/zh active Active
- 2015-07-10 NZ NZ728019A patent/NZ728019A/en unknown
- 2015-07-10 ES ES15738884T patent/ES2774428T3/es active Active
- 2015-07-10 SG SG11201610777VA patent/SG11201610777VA/en unknown
- 2015-07-10 PT PT157388844T patent/PT3169706T/pt unknown
- 2015-07-10 IL IL296633A patent/IL296633A/en unknown
- 2015-07-10 KR KR1020237033792A patent/KR20230146665A/ko active Pending
- 2015-07-10 EP EP19213033.4A patent/EP3763738A1/en active Pending
- 2015-07-10 HR HRP20200283TT patent/HRP20200283T1/hr unknown
- 2015-07-10 AU AU2015286569A patent/AU2015286569B2/en active Active
- 2015-07-10 PL PL15738884T patent/PL3169706T3/pl unknown
- 2015-07-10 EA EA201790173A patent/EA201790173A1/ru unknown
- 2015-07-10 SI SI201531118T patent/SI3169706T1/sl unknown
- 2015-07-10 KR KR1020177003473A patent/KR102586656B1/ko active Active
- 2015-07-10 WO PCT/EP2015/065900 patent/WO2016005593A1/en not_active Ceased
- 2015-07-10 JP JP2017501287A patent/JP6701162B2/ja active Active
- 2015-07-10 LT LTEP15738884.4T patent/LT3169706T/lt unknown
-
2016
- 2016-12-12 IL IL249512A patent/IL249512B2/en unknown
- 2016-12-13 ZA ZA2016/08609A patent/ZA201608609B/en unknown
-
2018
- 2018-03-28 US US15/938,961 patent/US10201607B2/en active Active
-
2019
- 2019-01-15 US US16/248,402 patent/US10765743B2/en active Active
- 2019-02-07 US US16/270,317 patent/US10500276B2/en active Active
- 2019-11-04 US US16/673,383 patent/US20200171152A1/en not_active Abandoned
-
2020
- 2020-03-04 CY CY20201100192T patent/CY1122721T1/el unknown
- 2020-05-01 JP JP2020080943A patent/JP2020141682A/ja active Pending
-
2021
- 2021-07-15 AU AU2021205074A patent/AU2021205074B2/en active Active
-
2023
- 2023-02-28 US US18/175,894 patent/US20240091352A1/en active Pending
- 2023-11-24 JP JP2023198745A patent/JP2024026158A/ja active Pending
-
2025
- 2025-03-10 AU AU2025201717A patent/AU2025201717A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017522871A5 (enExample) | ||
| HRP20200283T1 (hr) | Protutijela koja se vežu na axl | |
| KR102190548B1 (ko) | 항-her2 항체-약물 접합체 | |
| US20210380680A1 (en) | Anti-claudin antibodies and uses thereof | |
| JP2020501531A5 (enExample) | ||
| JP2018525354A5 (enExample) | ||
| JP2017186337A5 (enExample) | ||
| JP2018520991A5 (enExample) | ||
| CN107735093A (zh) | Cd123抗体和其结合物 | |
| HRP20200551T1 (hr) | Axl-specifični konjugati protutijelo-lijek za liječenje raka | |
| JPWO2021142002A5 (enExample) | ||
| JP2010535713A5 (enExample) | ||
| CN116390772A (zh) | 新型美登素类似物作为adc有效载荷及其在癌症治疗中的用途 | |
| JP2026501556A (ja) | 抗体薬物複合体 | |
| JPWO2020176497A5 (enExample) | ||
| KR20240095534A (ko) | 화학요법 내성 암의 치료 방법에서 사용하기 위한 항체-약물 접합체 | |
| WO2024088388A1 (en) | Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof | |
| WO2024050031A2 (en) | Novel camptothecin derivatves as antibody-drug conjugates (adc) payloads | |
| CA3147887A1 (en) | Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas | |
| CN113329769A (zh) | 具有反应性精氨酸的抗体化合物及相关的抗体药物缀合物 | |
| WO2024208354A1 (en) | Antibody drug conjugates | |
| NZ766131B2 (en) | Antibodies binding AXL | |
| NZ766128B2 (en) | Antibodies binding AXL | |
| JP2025529266A (ja) | ヒト化抗ｐｖｒ抗体の薬物複合体 | |
| WO2026011073A1 (en) | Antibody drug conjugates |